Novo blames US health system after criticism over Wegovy price, Bloomberg reports

Novo Nordisk (NOVOb.CO) said it retains about 60% of the list price of its popular diabetes and obesity drugs - Ozempic and Wegovy - after rebates and fees paid to middlemen in the United States, according to a Bloomberg report on Tuesday.